EMA Authorised: Mozobil (Plerixafor) — Sanofi B.V.

View source ↗

Summary

The EMA authorised Mozobil (plerixafor) from Sanofi B.V. for multiple myeloma and lymphoma indications, including use in hematopoietic stem cell transplantation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Mozobil (plerixafor)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma;Hematopoietic Stem Cell Transplantation;Lymphoma. MAH: Sanofi B.V.. Decision date: 16/07/2024